




VENMAX

DRUGS AND PHARMACEUTICALS LIMITED.

VENMAX DRUGS AND PHARMACEUTICALS LIMITED				
Shed No.22, Plot No.84, Phase-1, IDA, Cherlapally, Hyderabad, Rangareddy, Telangana, Pincode-500055 (CIN: L24230TG1988PLC009102)				
(Rs. in Lakhs)				
Statement Of Un-Audited Results For The Quarter Ended 30th June 2023				
Particulars	Quarter ended June 30,2023	Quarter ended March 31,2023	Quarter ended June 30,2022	Year ended March 31,2023
	(Un audited)	(Audited)	(Un audited)	(Audited)
Income				
Revenue from operations	-	-	-	-
Total Revenue from operations				
Other income	5.00	26.93	5.00	41.93
Total Income	5.00	26.93	5.00	41.93
Expenses				
Purchases	-	-	-	-
Changes in Inventory	-	-	-	-
Employee benefits expense	0.60	0.73	0.30	3.02
Finance costs	-	-	-	-
Depreciation and amortization expense	0.18	0.20	0.20	0.81
Other expenses	2.42	6.78	1.37	15.53
Total Expenses	3.20	7.71	1.87	19.36
Profit before tax	1.80	19.22	3.13	22.57
Tax expense				
(1) Current tax	-	-	-	-
(2) Deferred tax	(0.00)	(0.05)	0.16	0.01
Net Profit for the Period	1.80	19.27	2.97	22.56
Other comprehensive income (OCI)				
(a) (i) Items that will not be reclassified to profit or loss	-	-	-	-
(ii) Tax on items that will not be reclassified to profit or loss	-	-	-	-
(b) (i) Items that will be reclassified to profit or loss	-	-	-	-
(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
Total Other Comprehensive income	-	-	-	-
Total Comprehensive income	1.80	19.27	2.97	22.56
Paid-up Equity Share Capital (Rs.,10/- per Equity Share)	523.89	523.89	523.89	523.89
Other Equity	-	-	-	(595.34)
Earnings per equity share (Face value of Rs.10/- each)				
(1) Basic	0.03	0.37	0.06	0.43
(2) Diluted	0.03	0.37	0.06	0.43
Notes				
a)The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting standards) Rules. 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) rules 2016.				
b) The above Financial results recommended by the Audit Committee are considered and approved by the Board of Directors at their meeting held on 11th August ,2023				
c) The above statement have been prepared to the extent applicable, in accordance with the companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013 and other recognised Accounting Practices and Policies adopted by the Company w.e.f.01.04.2017. The financial results of the previous periods duly complied with Ind AS have not been subjected to review or audit, however, the Management has exercised necessary diligence to ensure that the financial results provide a true and fair view of the Company's affairs.				
d) The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.				
e) The Company is engaged in activities of trading of bulk drugs, intermediates and biotech products.Hence Segment reporting is not applicable.				
For and on Behalf of Board of Directors				
 <i>N. Krishnaiah</i> N Krishnaiah Director DIN:- 07279009				
Date : 11-08-2023				
Place : Hyderabad.				